2.0
2 Feb 2016
Former employee, more than 10 years
Richmond, VA
Recommend
CEO approval
Business outlook
Pros
Good/Excellent Products in the respiratory market place. The overall respiratory product portfolio has been the best in the US.
Cons
Limited patent life of major Rx product, Advair. Other newer GSK products have not filled the economic void left by new competitors. Business constraints due to corporate violations and the FDA CIA (corporate integrity agreement) has mangled the company and its ability to be healthy, and productive.